Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...
A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...
A recent survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of ...
The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...
Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...
This fall, Fierce Pharma Marketing launched a running series of Q&A features celebrating up-and-comers in our corner of the ...
| Adopting an RTU vial setup for aseptic filling process can help optimize operational efficiency, reduce TCO, and comply ...
When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...
Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results